OncoTargets and Therapy (Sep 2022)

Chronological Liquid Biopsy Reveals the Impact of Platinum-Based Chemotherapy on a Prostate Cancer Patient’s CDK12 Mutation: A Case Report

  • Zhu S,
  • Bao Y,
  • Zheng L,
  • Zhao J,
  • Chen Y,
  • Huang R,
  • Sun G,
  • Zhao F,
  • Zhang X,
  • Liang J,
  • Chen J,
  • Wang Z,
  • Ni Y,
  • Chen N,
  • Shen P,
  • Zeng H

Journal volume & issue
Vol. Volume 15
pp. 947 – 952

Abstract

Read online

Sha Zhu,1,* Yige Bao,1,* Linmao Zheng,2,* Jinge Zhao,1 Yuntian Chen,3 Rui Huang,4 Guangxi Sun,1 Fengnian Zhao,1 Xingming Zhang,1 Jiayu Liang,1 Junru Chen,1 Zhipeng Wang,1 Yuchao Ni,1 Ni Chen,2 Pengfei Shen,1 Hao Zeng1 1Department of Urology, West China Hospital, Sichuan University, Chengdu, People’s Republic of China; 2Department of Pathology, West China Hospital, Sichuan University, Chengdu, People’s Republic of China; 3Department of Radiology, West China Hospital, Sichuan University, Chengdu, People’s Republic of China; 4Department of Nuclear Medicine, West China Hospital, Sichuan University, Chengdu, People’s Republic of China*These authors contributed equally to this workCorrespondence: Pengfei Shen; Hao Zeng, Department of Urology, West China Hospital, Sichuan University, Chengdu, 610041, People’s Republic of China, Tel +86-18980602129, Fax +86-28-8542-2451, Email [email protected]; [email protected]; [email protected]: CDK12 (Cyclin-Dependent Kinase 12)-mutated prostate cancer patients often respond badly to current therapies. Immunotherapy and platinum-based chemotherapy are recommended based on the molecular features of CDK12-mutated tumors, but the reported patient outcomes are still unsatisfying. Here we report a prostate cancer patient with CDK12 somatic mutation who received multiple therapy options, including platinum-based chemotherapy and immunotherapy. His sequential circulating tumor DNA (ctDNA) -based liquid biopsy tests showed that his original CDK12 mutation fell undetectable twice. This phenomenon was observed only when he was responding well to platinum-based chemotherapy. His responses to immunotherapy were not satisfying. This case indicates that platinum-based chemotherapy can be a good option for treating patients with CDK12 mutation. More importantly, dynamic ctDNA-based liquid biopsies to monitor patients’ CDK12 mutation status are critical in evaluating patients’ response and tolerance during platinum-based chemotherapy, therefore may lead to a better overall prognosis. In conclusion, CDK12-mutated prostate cancer patients are likely to benefit from platinum-based chemotherapy, especially with the help of dynamic ctDNA-based liquid biopsies to monitor their CDK12 mutation status.Keywords: CDK12, liquid biopsy, platinum, prostate cancer, case report

Keywords